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Abstract: 
 
Purpose: The aim of this study is to examine and compare with the validated, paper/pencil 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-
Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20), the psychometric 
properties of three electronically administered patient reported outcome (PRO) measures of 
chemotherapy-induced peripheral neuropathy (CIPN): (1) the two neuropathy items from the 
National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology 
Criteria for Adverse Events (PRO-CTCAE), (2) the QLQ-CIPN20, and (3) the 0–10 Neuropathy 
Screening Question (NSQ). Methods: We employed a descriptive, cross-sectional design and 
recruited 25 women with breast cancer who were receiving neurotoxic chemotherapy at an 
academic hospital. Participants completed the paper/pencil QLQ-CIPN20 and electronic versions 
of the QLQ-CIPN20, PRO-CTCAE, and NSQ. Internal consistency reliability, intraclass 
correlation, and concurrent and discriminant validity analyses were conducted. Results: The 
alpha coefficients for the electronic QLQ-CIPN20 sensory and motor subscales were 0.76 and 
0.75. Comparison of the electronic and paper/pencil QLQ-CIPN20 subscales supported mode 
equivalence (intraclass correlation range >0.91). Participants who reported the presence of 
numbness/tingling via the single-item NSQ reported higher mean QLQ-CIPN20 sensory subscale 
scores (p < 0.001). PRO-CTCAE neuropathy severity and interference items correlated well with 
the QLQ-CIPN20 electronic and paper/pencil sensory (r = 0.76; r = 0.70) and motor 
(r = 0.55; r = 0.62) subscales, and with the NSQ (r = 0.72; r = 0.44). Conclusion: These data 
support the validity of the electronically administered PRO-CTCAE neuropathy items, NSQ, and 
QLQ-CIPN20 for neuropathy screening in clinical practice. The electronic and paper/pencil 
versions of the QLQ-CIPN can be used interchangeably based on evidence of mode equivalence. 
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Article: 
 
Chemotherapy-induced peripheral neuropathy (CIPN) occurs in up to 64% of individuals 
receiving neurotoxic chemotherapy (e.g., platinums and taxanes) for the treatment of oncological 
and hematological malignancies [1, 2, 3, 4, 5, 6]. Individuals experience a variety of symptoms 
such as numbness, tingling, and burning in the extremities that persist for months to years after 
the completion of neurotoxic anti-cancer therapy [7, 8]. These symptoms may negatively affect 
physical function and quality of life and may necessitate chemotherapy dose reductions or 
discontinuation. These changes in therapy can compromise treatment efficacy and increase the 
risk of mortality [5, 9, 10]. 
 
Currently, several patient- and provider-related barriers hinder CIPN assessment in clinical 
practice. First, patients often do not accurately report their symptoms due to difficulty describing 
their symptoms (e.g., numbness and tingling) [11, 12]. Patients may also be reluctant to report 
CIPN symptoms for fear that doing so may lead to dose reductions or treatment discontinuation 
[13]. Further, clinicians often lack the time and expertise necessary to complete comprehensive 
neuropathy examinations (e.g., reflex, vibration, and strength assessments) [11, 14, 15] and there 
are currently few well-validated neuropathy self-report screening instruments for use in clinical 
practice. 
 
Another barrier to CIPN assessment in clinical practice is that there is no “gold standard” 
measure. While a few psychometrically sound self-report CIPN measures are available, complex 
scoring and administration complicate their use in clinical practice [16, 17]. For example, the 
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire-Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20) patient 
reported outcome (PRO) measure has been extensively used to evaluate CIPN severity in the 
USA and Europe [18]. The QLQ-CIPN20’s psychometric properties have been evaluated 
[18, 19], but its administration (paper/pencil) and scoring may be too cumbersome to make it 
feasible for use in busy clinical settings. 
 
Another measure commonly used by clinicians to grade CIPN severity is the peripheral 
neuropathy items of the National Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) [20]. However, the measurement properties (e.g., reliability, validity, and 
responsiveness) of those items may be suboptimal [17, 19, 21, 22]. Moreover, provider-reported 
CTCAE grades for neuropathy do not correlate strongly with patient-reported CIPN severity 
[23]. Recent evidence suggests that, compared to clinician reporting alone, adding patient 
reporting of cancer treatment-related symptoms may provide a more reliable and valid 
measurement of symptom severity [21, 24, 25]. In addition, measures that quantify the patient’s 
perspective may encourage the discussion of symptoms between patients and clinicians [26]. To 
encourage patient reporting, the National Cancer Institute initiated development of the Patient-
Reported Outcomes version of the CTCAE (PRO-CTCAE™) [27, 28], which has since 
demonstrated generally favorable measurement properties in evaluations using both quantitative 
and qualitative techniques [27, 28, 29]. While this measure, which has two items addressing 
CIPN, holds promise for improving CIPN measurement, the PRO-CTCAE neuropathy items 
have not been evaluated in comparison to well-validated CIPN measures. 
 
One way to facilitate efficient CIPN assessment in clinical settings is through the use of 
technology that allows patients to self-report their CIPN symptoms using brief, validated 
measures administered electronically. The use of such technology may alert clinicians to the 
presence of CIPN symptoms and lead to the prioritization of CIPN assessment. However, the 
psychometric properties of electronic versions of PRO CIPN measures have not yet been tested. 
Thus, the primary purpose of this study was to compare to the well-validated, paper/pencil QLQ-
CIPN20 the psychometric properties of electronic versions of three patient-reported CIPN 
outcome measures: (1) the two PRO-CTCAE numbness and tingling severity and interference 
items, (2) the QLQ-CIPN20, and (3) the 0–10 Neuropathy Screening Question (NSQ). The 
secondary aims were to examine the mode equivalence of the paper/pencil and electronic 
versions of the QLQ-CIPN20, and to evaluate the concurrent validity of the psychometric 
properties of the PRO-CTCAE neuropathy items with the clinician-reported CTCAE. 
 
Methods 
 
Design, sample, and setting 
 
This study employed a descriptive, cross-sectional design. Convenience sampling was used to 
recruit 25 individuals with breast cancer receiving neurotoxic chemotherapy from a 
comprehensive cancer center. To be eligible, participants had to be 18 years or older with a 
diagnosis of breast cancer, English-speaking and -reading, capable of using a computer, and 
receiving neurotoxic chemotherapy. Each participant signed informed consent before 
participation. The study was approved by the IRB at the University of Michigan. 
 
Measures 
 
EORTC QLQ-CIPN20. This 20-item self-report measure quantifies sensory (e.g., 
numbness/tingling), motor (e.g., problems with ambulation due to numbness/tingling), and 
autonomic (e.g., dizziness) CIPN symptoms and associated functional limitations. The recall 
period is the past 7 days. Items are scored using a one to four scale, with one representing “not at 
all” and four representing “very much” [18]. Each subscale is linearly transformed from a 0 (no 
neuropathy) to 100 (severe neuropathy) point scale [30]. The internal consistency reliability 
alpha coefficients for the sensory, motor, and autonomic subscales has been reported as 0.88, 
0.88, and 0.78, respectively [19]. The sensory and motor subscales are moderately to highly 
responsive to change (d = 0.82 and 0.48) [19]. The capacity of the QLQ-CIPN20 to distinguish 
those who did and did not receive neurotoxic chemotherapy confirms its discriminant validity 
[19]. 
 
CTCAE—sensory neuropathy grading criteria. Neuropathy was also evaluated by study 
providers using the CTCAE (version 4.0) [20]. The CTCAE grading criteria for sensory 
neuropathy are based on the evaluation of objective and subjective parameters (e.g., reflexes, 
tingling, alterations in activities of daily living). Toxicity is graded from 1 to 5; higher grades 
represent worse sensory neuropathy (1 = asymptomatic and/or loss of deep tendon reflexes; 5 = 
death). The scale is subject to floor effects, and has been shown to lack sensitivity to detect small 
changes in neuropathy due to its broad scoring categories (e.g., diminished reflexes and 
paresthesias are grouped into one category) [17, 19, 22]. The scale also has low inter-rater 
reliability and low concurrent validity when compared to patient-reported measures of 
neuropathy with strong measurement properties [16, 17, 19]. Despite its limitations, the CTCAE 
was used in this study because it is currently the standard measure used in most oncology clinical 
trials and we were interested in assessing its performance when compared to the PRO-CTCAE. 
 
PRO-CTCAE—numbness/tingling severity and interference items. The PRO-CTCAE item 
library contains 124 items reflecting 78 symptomatic cancer treatment-related symptomatic 
toxicities. The recall period is the past 7 days. Items are scored from zero to four, and higher 
scores represent greater symptom severity and interference [27, 28]. Previous studies have 
supported the content validity, concurrent validity, responsiveness of change, and test-retest 
reliability of the PRO-CTCAE item library [27, 29]. For this study, we evaluated the two PRO-
CTCAE items addressing CIPN, which ask patients to rate the severity of the numbness and 
tingling in their hands or feet (severity item) at its worst in the past 7 days, and how much these 
symptoms have interfered with usual or daily activities (interference item). The CIPN 
numbness/tingling severity and interference items have demonstrated moderate test-retest 
reliability as evidenced by intraclass correlation coefficients (ICCs) of 0.80 and 0.55, 
respectively. Also, the PRO-CTCAE numbness/tingling severity (r = 0.32) and interference 
items (r = 0.34) have exhibited low-moderate correlations with the EORTC QLQ-C30 [27], 
demonstrating moderate reliability and validity in comparison to measures of quality of life. 
However, these items have not yet been compared to validated CIPN measures. 
 
NSQ. The NSQ is an electronic CIPN screening item that was created specifically for use within 
the Carevive® Cancer Care Planning System. Patients first indicate (yes/no) if they have 
experienced numbness and tingling in their hands or feet in the past 7 days. If they respond yes, 
patients then rate the severity of the numbness and tingling in their hands or feet using a zero to 
ten (worse symptom severity) numerical rating scale. The NSQ’s psychometric properties have 
not been previously evaluated. 
 
Procedures 
 
Participants reported their CIPN symptoms using a web-based cancer care planning system 
(Carevive®) that was designed to facilitate the collection of patient- and provider-reported data 
(e.g., medical/cancer history and patient-reported outcomes) and to generate a customized patient 
care plan comprised of CIPN treatment recommendations. A previous study has shown that the 
Carevive® Care Planning system possesses a high degree of patient-related feasibility, usability, 
acceptability, and satisfaction [31]. Patients interacted with the computerized care planning 
system using a tablet computer (screen size = 9.4 × 6.6 in) while waiting for their scheduled 
outpatient provider visit. At the patient’s third and final study visit, and after becoming 
comfortable using the tablet to report their cancer symptoms, the patients completed the 
electronic versions of the QLQ-CIPN20, NSQ, and PRO-CTCAE. These measures were 
embedded within the computerized care planning system. In the exam room, advanced practice 
providers graded their patients’ CIPN severity using a paper/pencil version of the CTCAE. After 
the provider left the room, trained study personnel administered the paper/pencil version of the 
QLQ-CIPN20. 
 
Statistical analysis 
 
All data analysis procedures were conducted using Statistical Package for the Social Sciences 
version 23.0, and R 3.3.0. The analytic approaches used to test internal consistency reliability, 
concurrent validity, discriminant validity, and mode equivalence are described below. 
 
Reliability 
 
The internal consistency reliability of the QLQ-CIPN20’s sensory and motor subscales 
(paper/pencil and electronic versions) was evaluated using Cronbach’s alpha. Pearson’s 
correlation was calculated for the two-item autonomic scale (paper/pencil and electronic 
versions) because Cronbach’s alpha is a poor measure of internal consistency when the scale 
contains less than 3–4 items [32]. A Cronbach’s alpha coefficient ≥0.8 was expected for each 
subscale. 
 
Concurrent validity 
 
Using multiple Pearson correlations, the concurrent validity of the QLQ-CIPN20, PRO-CTCAE, 
and NSQ was evaluated. Pearson correlations were calculated to evaluate the associations among 
the paper/pencil QLQ-CIPN20, electronic PRO-CTCAE, and NSQ; among the electronic QLQ-
CIPN20, PRO-CTCAE, and NSQ; and between the electronic PRO-CTCAE numbness/tingling 
severity and interference items and clinician-reported CTCAE grade for sensory neuropathy. 
 
Discriminant validity 
 
The discriminant validity of the NSQ was evaluated using independent-sample t tests to examine 
differences in QLQ-CIPN20 subscales scores between patients who did and did not report 
neuropathy symptoms. We hypothesized that those who reported numbness and tingling via the 
NSQ would have significantly higher mean scores on the sensory subscale of the QLQ-CIPN20 
than those who did not. We did not expect to find significant differences on the motor and 
autonomic subscales of the QLQ-CIPN20 because those scales do not contain questions 
pertaining to numbness and tingling. Additionally, sensitivity and specificity analyses were 
conducted to investigate the NSQ’s accuracy as a screening measure, as compared to the QLQ-
CIPN20 sensory subscale. 
 
Mode equivalence 
 
Mode equivalence between the paper/pencil and electronic QLQ-CIPN20 subscales (i.e., 
sensory, motor, autonomic) and individual items were evaluated by assessing (1) the magnitude 
of the difference in mean subscale scores between modes and (2) the level of between-mode 
agreement. The magnitude of the differences between mean scores was evaluated by determining 
standardized effects sizes (Cohen’s d). Cohen’s d was obtained by dividing the mean difference 
by the pooled standard deviation [34]. Differences in mean subscale and item scores between the 
two modes were assessed using paired t tests. An effect size of 0.20 is considered a small effect 
size and values below this benchmark were interpreted as supporting the comparability of 
responses collected using different modes of administration [33, 34]. Mode equivalence was 
further evaluated using ICC using the ICC (3.1), in the notation of Shrout and Fleiss [35], in a 
two-way analysis of variance model. An ICC of >0.7 was expected for each comparison between 
the paper/pencil and electronic subscales [36]. 
 
Results 
 
Sample characteristics 
 
Stage IV breast cancer, as defined by the American Joint Committee on Cancer [37], was the 
most common cancer diagnosis (36%); the remainder of the participants had non-metastatic 
breast cancer. Most participants had previously undergone surgery (64%) or radiation therapy 
(48%) for cancer treatment. Almost all participants were receiving neurotoxic chemotherapy: 
paclitaxel (72%) or docetaxel (24%). Based on the cumulative dose of paclitaxel or docetaxel 
received, 63% of these participants fell in the moderate CIPN risk category [38, 39, 40, 41]. 
Eighty percent of the participants were white, 88% had completed some college education, and 
100% had previously used a computer before beginning the study (Table 1). Twenty three of the 
participants completed all the required surveys; however, one of the 23 did not report scores for 
the autonomic scale of the paper/pencil version of the QLQ-CIPN20 (n = 22). 
 
Table 1. Baseline characteristics of enrolled patients (N = 25) 
Variable Frequency (%) 
Gender 
 Female 25 (100) 
Race 
 American Indian or Alaska native 1 (4) 
 Asian 2 (8) 
 Black or African American 2 (8) 
 White 20 (80) 
Ethnicity 
 Hispanic or Latino 1 (4) 
 Not Hispanic or Latino 24 (96) 
Education 
 High school or less 3 (12) 
 Some college 7 (28) 
 Undergraduate degree 10 (40) 
 Graduate degree 5 (20) 
Employment status 
 Employed 12 (48) 
 Retired 6 (24) 
 Homemaker 2 (8) 
 Disabled 5 (20) 
Marital status 
 Married or partnered 19 (76) 
 Single 2 (8) 
 Divorced 4 (16) 
Variable Frequency (%) 
Cancer stagea 
 Stage I 3 (12) 
 Stage II 6 (24) 
 Stage III 7 (28) 
 Stage IV 9 (36) 
Hormone receptor status 
 Positive 18 (72) 
 Negative 7 (28) 
Her2/neu status 
 Positive 12 (48) 
 Negative 13 (52) 
Surgery 
 No surgery 9 (36) 
 Lumpectomy 7 (28) 
 Mastectomy 9 (36) 
Chemotherapy type 
 Paclitaxel 18 (72) 
 Docetaxel 6 (24) 
 Carboplatinb 1 (4) 
Cumulative M2 dose category: Paclitaxel (n = 18)c 
 Low risk: 0–700 3 (16.7) 
 Moderate risk: 700–1400 9 (50) 
 High risk: >1400 6 (33.3) 
Cumulative M2 dose category: Docetaxel (n = 6)d 
 Low risk: 0–300 0 
 Moderate risk: 300–600 6 (100) 
 High risk: > 600 0 
Radiation therapy status 
 Planned, not started 8 (32) 
 Complete 4 (16) 
 Not planned or receiving 13 (52) 
This table describes the demographic characteristics of the recruited sample at baseline 
aCancer stage was determined based on the American Joint Committee on Cancer (AJCC) Cancer Staging 
Manual (7th Edition) [37] 
bNo data available to guide cumulative dose category 
cCumulative M2 dose ranges for paclitaxel-induced neuropathy risk were generated based upon dose-related 
neurotoxicity patterns described in the literature [40, 41] 
dCumulative M2 dose ranges for docetaxel-induced neuropathy risk were generated based upon dose-related 
neurotoxicity patterns described in the literature [42, 43] 
 
Descriptive statistics for the QLQ-CIPN20, CTCAE, PRO-CTCAE, and NSQ are provided in 
Table 2. Patients’ mean scores on the sensory, motor, and autonomic subscales of the electronic 
and paper/pencil QLQ-CIPN20 were similar. The mean score on the CTCAE was 1.0 (SD = 0), 
while the mean scores on the PRO-CTCAE numbness/tingling severity and interference items 
were 0.83 (SD = 0.83, range = 0–2) and 0.44 (SD = 0.66, range = 0–2). The percentage of 
participants reporting “0” scores, the lowest possible score for the PRO-CTCAE 
numbness/tingling severity and interference items, were 43.48 and 65.22%, respectively. All 
participants were given CTCAE grades of 1, the lowest possible score. Score comparisons 
between the CTCAE and PRO-CTCAE for each patient are illustrated in Fig. 1. Lastly, the mean 
score on the NSQ was 1.91 (SD = 2.31, range = 0–7). 
 
Table 2. QLQ-CIPN20, CTCAE, and NSQ sample statistics (N = 23) 
Scale Mean Median 
Standard 
deviation Range 
Proportion 
at floor 
Proportion 
at ceiling 
QLQ-CIPN20 
 Paper/pencil sensory subscale 11.43 7.41 11.33 0–44 21.8 0 
 Electronic sensory subscale 12.72 7.02 11.97 0–44 13.0 0 
 Paper/pencil motor subscale 7.75 4.17 10.33 0–38.08 47.8 0 
 Electronic motor subscale 8.33 4.17 11.10 0–37.5 43.5 0 
 Paper/pencil autonomic subscale (n = 22) 6.82 0.0 11.10 0–33.33 68.2 0 
 Electronic autonomic subscale 7.25 0.0 11.04 0–33.33 65.2 0 
CTCAE 
 CTCAE grade 1.0 1.0 0 1 100 0 
 PRO-CTCAE—Numbness/tingling item 0.83 1.0 0.83 0–2 43.5 0 
 PRO-CTCAE—interference item 0.44 0.0 0.66 0–2 65.2 0 
NSQ 
 NSQ 1.91 1.0 2.31 0–7 47.8 0 
This table describes descriptive statistics (mean, median, SD, range, % at floor, % at ceiling for the QLQ-CIPN20 
subscales, CTCAE, and PRO-CTCAE CIPN items, and NSQ 
For all scales, higher scores represent greater CIPN symptom severity (e.g., increased numbness and tingling) and/or 
associated functional impairment due to CIPN symptoms 
 
 
Figure 1. PRO-CTCAE Scores vs. CTCAE Grades. This figure illustrates the differences in 
PRO-CTCAE numbness and tingling severity and interference item scores compared to provider-
reported CTCAE sensory neuropathy grades for each patient enrolled in the study. Note: case 7 
was missing CTCAE grade and PRO-CTCAE scores. CTCAE scores appear to be higher than 
PRO-CTCAE item scores because the CTCAE is scored from 1 to 5 (1 = minimal neuropathy 
symptoms), whereas the PRO-CTCAE items are scored from 0 to 4 (0 = no neuropathy) 
 
Reliability 
 
Cronbach’s alphas for the sensory and motor subscales of the electronic QLQ-CIPN20 were 0.76 
and 0.75, and the two items of the autonomic scale were not correlated with one another 
(r = −0.02, p > 0.05). The Cronbach’s alpha of the paper/pencil QLQ-CIPN20 sensory and motor 
subscales were 0.79 and 0.75. The two items of the paper/pencil autonomic scale were also not 
correlated (r = 0.02). 
 
Concurrent validity 
 
The sensory and motor subscales of the paper/pencil and electronic QLQ-CIPN20 were 
significantly correlated to both PRO-CTCAE items. The NSQ was significantly correlated with 
the sensory subscale of the paper/pencil (r = 0.66) and electronic (r = 0.67) QLQ-CIPN20 and 
with both PRO-CTCAE items (severity r = 0.72; interference r = 0.44) (Table 3). Further, since 
all patients were graded by clinicians as having CTCAE grade 1 sensory neuropathy, the planned 
evaluation of the associations between CTCAE grades and PRO-CTCAE scores could not be 
pursued. 
 
Table 3. QLQ-CIPN20, NSQ, and PRO-CTCAE correlations (N = 23) 
Scale Electronic QLQ-CIPN20 Paper/Pencil QLQ-CIPN20 
PRO-CTCAE 
numbness and tingling NSQ 
  Subscale Sensory Motor Autonomic Sensory Motor Autonomic 
(n = 22) 
Severity Interference   
PRO-CTCAE 
numbness and 
tingling 
Severity 0.76a 0.55b 0.14 0.70a 0.62 0.09 1     
  Interference 0.78a 0.77a 0.28 0.72a 0.80a 0.21 0.72a 1   
NSQ   0.69a 0.26 −0.09 0.66a 0.28 −0.16 0.72a 0.44b 1 
This table describes correlations between mean paper/pencil and electronic QLQ-CIPN20, PRO-CTCAE, and NSQ 
mean scores. 
No adjustments for multiple comparisons were made 
aCorrelation significant at the 0.01 level (two-tailed) 
bCorrelation significant at the 0.05 level (two-tailed) 
 
Discriminant validity 
 
Twelve participants who reported experiencing numbness/tingling via the NSQ (score ≥1) also 
reported significantly higher mean scores for the electronic QLQ-CIPN20 sensory subscale 
(Yes: M = 21.3, SD = 10.6; No: M = 3.4, SD = 2.6), t(12.43) = −5.67 (p < 0.001) and the 
paper/pencil sensory scale (Yes: M = 19.1, SD = 10.6; No: M = 3.0, SD = 3.2), t(13.21) = −5.02 
(p < 0.001) than those who did not. Thus, this item demonstrated acceptable discriminant 
validity. As expected, significant differences between those who did/did not report 
numbness/tingling on the NSQ were not observed among the motor and autonomic subscales of 
the electronic and paper/pencil QLQ-CIPN20. 
 
Using the QLQ-CIPN20 sensory subscale, the NSQ had a sensitivity of 0.67 (CI = 0.41, 0.87) 
and specificity of 1.0 (CI = 0.36, 1.0). Sensitivity and specificity testing for the motor and 
autonomic subscales was not warranted as there were no significant differences between the 
motor and autonomic QLQ-CIPN20 subscales when we compared those who did/did not report 
numbness/tingling on the NSQ. 
 
Table 4. Standardized effect sizes for QLQ-CIPN20 scale comparisons 
QLQ-CIPN20 subscale or item 
Standardized effect size paper/pencil vs. 
electronic Confidence interval 
Subscale 
 Sensory subscale 0.11 −0.07, 0.29 
 Motor subscale 0.05 −0.1, 0.21 
 Autonomic subscale No variancea NA 
Individual items 
 Sensory subscale 
  Tingling in hands 0.16 −0.02, 0.34 
  Tingling in toes 0.0 −0.15, 0.15 
  Numbness in hands 0.13 −0.19, 0.45 
  Numbness in toes 0.06 −0.22, 0.34 
  Pain in hands 0.0 −0.36, 0.36 
  Pain in toes 0.0 −0.51, 0.51 
  Walking problems 0.09 −0.21, 0.38 
  Difficulty distinguishing hot/cold No variancea NA 
  Hearing problems 0.08 −0.08, 0.24 
 Motor subscale 
  Cramps in hands 0.19 −0.07, 0.44 
  Cramps in feet 0.15 −0.06, 0.36 
  Trouble holding pencil/writing 0.0 −0.28, 0.28 
  Trouble grasping small objects 0.14 −0.05, 0.33 
  Trouble opening jars 0.0 −0.15, 0.15 
  Problems walking due to foot drop No variancea NA 
  Trouble walking upstairs 0.02 −0.40, 0.44 
  Trouble driving/feeling pedals in car −0.53b −1.12, 0.07 
 Autonomic subscale 
  Dizziness 0.0 NA 
  Blurred vision No variancea NA 
This table describes standardized effect sizes for the difference between paper/pencil and electronic QLQ-CIPN20 
mean scores (per subscale and item) 
aNo variance indicates that scores between measures were identical and thus an effect size of the difference could 
not be computed 
bEffect size estimate may have been influenced by the presence of three outliers 
 
Mode equivalence 
 
Tables 4 and 5 describe the results of the mode equivalence analysis. The effect sizes (using 
Cohen’s d) of the mean differences for the sensory and motor subscales were 0.11 (CI = −0.7, 
0.29) and 0.05 (CI = −0.1, 0.21), respectively. At the item level, a majority (18/19) of the QLQ-
CIPN20 items had effect sizes smaller than 0.20 when the mean differences between modes were 
examined. For the autonomic subscale, an effect size could not be calculated because there was 
no variance in the responses. The mode equivalence ICC for the sensory, motor, and autonomic 
subscales comparing the paper/pencil and electronic QLQ-CIPN20 were 0.91, 0.93, and 1.0, 
respectively. Lastly, 14/19 items of the QLQ-CIPN20 demonstrated high levels of between-mode 
agreement (ICC > 0.70). 
 
Table 5. Intraclass correlation coefficients for agreement between paper/pencil and electronic 
QLQ-CIPN20 scores 
QLQ-CIPN20 scales/items ICC for electronic vs. paper/pencil 
Subscale 
 Sensory subscale 0.91 
 Motor subscale 0.93 
 Autonomic subscale 1.0 
Individual items 
 Sensory subscale 
  Tingling in hands 0.90 
  Tingling in toes 0.93 
  Numbness in hands 0.70 
  Numbness in toes 0.78 
  Pain in hands 0.63 
  Pain in toes 0.24 
  Walking problems 0.74 
  Difficulty distinguishing hot/cold 1.0 
  Hearing problems 0.93 
 Motor subscale 
  Cramps in hands 0.81 
  Cramps in feet 0.87 
  Trouble holding pencil/writing 0.78 
  Trouble grasping small objects 0.89 
  Trouble opening jars 0.94 
  Problems walking due to foot drop (motor 6) 1.0 
  Trouble walking upstairs 0.48 
  Trouble driving/feeling pedals in car a 
 Autonomic subscale 
  Dizziness 1.0 
  Blurred vision 1.0 
This table describes intraclass coefficients for the agreement between the paper/pencil and electronic QLQ-CIPN20 
subscales and items 
aThe ICC could not be calculated as the variance for the electronic administration of the QLQ-CIPN20 was zero 
 
Discussion 
 
The trivial effect sizes of the mean between-mode pairwise differences for the extensively 
validated paper/pencil subscales of the QLQ-CIPN20 [2, 18, 19] and the electronic version 
subscales provide support for use of the electronic QLQ-CIPN20 and for the use of pooled data 
from both modes of administration in analysis. In this study, the paper/pencil version of the 
QLQ-CIPN20 demonstrated lower ratings of internal consistency reliability than it has in other 
research [18, 19]: a previous study in a sample (n = 376) with prominent score variability 
demonstrated internal consistency reliability coefficients of 0.88, 0.88, and 0.78 for the sensory, 
motor, and autonomic subscales of the paper/pencil QLQ-CIPN20, respectively [19]. Given that 
the recommended minimum sample size recommended to calculate Cronbach’s alpha is 
approximately 300 participants, or 10 participants per item [42], the lower internal consistency 
reliability coefficients we found may be artifacts of our small sample (n = 23) and/or the low 
variability in responses. 
 
Our data demonstrate a lack of CTCAE score variability, consistent with other published reports 
showing that the provider-reported CTCAE neuropathy grades lack some sensitivity, may be 
subject to floor effects, and may not adequately distinguish subtle differences in neuropathy 
severity [17, 19, 21, 22]. Based on our and other investigator’s findings, the PRO-CTCAE may 
be a more precise and responsive measure of neuropathy severity than provider-reported CTCAE 
grades. Ideally, our observations should be replicated and extended in a larger and more diverse 
sample. Future studies should also examine responsiveness to change. 
 
The use of electronic PRO CIPN measures for the assessment of CIPN has important 
implications for practice. Utilizing PRO CIPN measures may simplify collecting neuropathy 
symptom data in the clinical setting because the measure can be administered in the waiting 
room (via tablet) or at the patients’ home (via patient portal) before the patients’ clinic visits. 
Previous research has demonstrated that an oncology care planning program that incorporated 
PRO CIPN measures had high ratings of patient-related feasibility, usability, acceptability, and 
satisfaction [43]. Additionally, brief and psychometrically sound electronic PRO CIPN measures 
may increase the feasibility of collecting neuropathy severity data in the clinical setting. For 
example, the one-item NSQ demonstrated strong concurrent validity when compared to the 
longer and more complex QLQ-CIPN20, which is clinically relevant because brief measures are 
more feasible for use in clinical practice than multi-item measures. In busy practice settings, a 
single-item screening measure could quickly alert providers that more comprehensive 
neuropathy examinations (e.g., reflexes/vibration) are warranted to assess the need for prompt 
treatment or chemotherapy dose modification to prevent severe and protracted CIPN. Lastly, the 
use of PRO CIPN measures may increase the efficiency, completeness, and accuracy of 
neuropathy data capture since patients will be directly reporting their CIPN symptoms into the 
electronic database (minimizing data entry errors) and allowing for completion of PRO measures 
between clinic visits. 
 
Limitations 
 
Several caveats should be considered in interpreting these study findings. First, the analysis was 
conducted using a small sample and in a homogeneous patient population (females with breast 
cancer who experienced low CIPN symptom severity while receiving neurotoxic chemotherapy). 
Thus, the results are preliminary and cannot be generalized to other populations (e.g., males, 
patients with other cancers and/or severe neuropathy). Further, in comparing modes, our study 
design did not control for order or memory effects when the participants completed the electronic 
and paper/pencil QLQ-CIPN20. Also, the mode equivalence analyses were underpowered, so our 
findings require replication in larger samples. The instruments were also administered at one 
time point, so we were unable to assess responsiveness to change in CIPN severity over time or 
determine the test-retest reliability of the measures. 
 
In conclusion, since CIPN is currently an underreported symptom of cancer treatment, valid and 
brief instruments are needed to strengthen the assessment of CIPN in clinical practice. This study 
provides preliminary evidence supporting the validity of the electronic PRO-CTCAE, QLQ-
CIPN20, and NSQ for the assessment of CIPN. However, due to the small sample of this study 
and the limited psychometric testing that was conducted, future studies are needed to more fully 
characterize the properties of these measures in diverse samples. Further testing may include the 
examination of the concurrent validity, responsiveness to change, and minimal clinically 
important difference of these electronic measures (i.e., electronic QLQ-CIPN20, PRO-CTCAE, 
and NSQ). With further psychometric testing, these electronic CIPN PRO measures may be 
integrated into clinical practice to facilitate the assessment of CIPN-related symptoms. 
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